Press Releases

Date Title
Toggle Summary Aeglea BioTherapeutics Announces U.S. and EU Orphan Drug Designations for ACN00177 for the Treatment of Homocystinuria
AUSTIN, Texas , Oct. 26, 2020 /PRNewswire/ --  Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced the U.S.
Toggle Summary Aeglea BioTherapeutics Announces Presentations on Arginase 1 Deficiency and Homocystinuria Programs at Two Upcoming Virtual Medical Meetings
AUSTIN, Texas , Oct. 5, 2020 /PRNewswire/ --  Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced the presentation of a poster on
Toggle Summary Aeglea BioTherapeutics to Participate in September Investment Conferences
AUSTIN, Texas , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will participate in
Toggle Summary Aeglea BioTherapeutics to Present at World Orphan Drug Congress USA 2020
AUSTIN, Texas , Aug. 18, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will participate in two
Toggle Summary Aeglea BioTherapeutics Reports Second Quarter 2020 Financial Results and Corporate Highlights
Pegzilarginase Showed Durable Clinical Response and Sustained Reduction in Plasma Arginine at  56 Week Analysis of Phase 1/2 Open-Label Extension Study Initiated Phase 1/2 Clinical Trial of ACN00177 for the Treatment of Homocystinuria AUSTIN, Texas , Aug.
Toggle Summary Aeglea BioTherapeutics to Present at BIO Digital 2020
AUSTIN, Texas , June 01, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will provide a corporate
Toggle Summary Aeglea BioTherapeutics Announces Change of Location of Annual Meeting of Stockholders to Be Held June 8, 2020
AUSTIN, Tx. , May 28, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced that, due to the public health
Toggle Summary Aeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology
   Pegzilarginase Showed Durable Clinical Response at 56 Week Analysis All Patients Demonstrated a Marked and Sustained Reduction in Plasma Arginine Favorable Safety Profile, Consistent with Previously Reported Results AUSTIN, Texas , May 26, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc.
Toggle Summary Aeglea BioTherapeutics to Present Late-Breaking 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology
AUSTIN, Texas , May 19, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will present a new 56 week
Toggle Summary Aeglea BioTherapeutics Reports First Quarter 2020 Financial Results and Corporate Highlights
Gross Proceeds of $138 Million from April 2020 Public Offering Extends Cash Runway Through 2022 Clinical Trial Application for ACN00177 Approved by MHRA; Progress Toward Phase 1/2 Clinical Trial in Homocystinuria Initiation AUSTIN, Texas , May 07, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics,
Toggle Summary Aeglea BioTherapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
AUSTIN, Texas , April 30, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions for rare and other high-burden diseases, today announced the closing of its public offering of
Toggle Summary Aeglea BioTherapeutics Announces Pricing of $120 Million Public Offering
AUSTIN, Texas , April 28, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases, today announced the pricing of an underwritten
Toggle Summary Aeglea BioTherapeutics Announces Proposed Public Offering
AUSTIN, Texas , April 27, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases, today announced a proposed underwritten public
Toggle Summary Aeglea BioTherapeutics Announces Approval of Clinical Trial Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)
AUSTIN, Texas , April 08, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions for diseases with high unmet medical need, today announced the approval of its Clinical Trial
Toggle Summary Aeglea BioTherapeutics Reports Fourth-Quarter and Full-Year 2019 Financial Results, Highlights Recent Milestones
Company Expects to Complete Enrollment in Phase 3 Trial for Patients with Arginase 1 Deficiency in Third Quarter of 2020, with Topline Data Expected in First Quarter of 2021 Phase 1/2 Trial for Patients with Homocystinuria to Initiate in Second Quarter of 2020 AUSTIN, Texas , Feb.